NCT06269445 2024-02-21
The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer
Sir Run Run Shaw Hospital
Phase 4 Unknown
Clinical Trials
51 trialsNCT06177288 2023-12-20
DEBIRI
Fudan University
Phase NA Unknown
NCT04034459 2023-11-14
AIO-KRK-0116
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT04310176 2023-11-13
REVOLUTION
National Cancer Institute, Naples
Phase 2 Unknown
NCT05785325 2023-10-31
RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT06060704 2023-10-11
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT06039202 2023-09-15
Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer
Holy Stone Healthcare Co., Ltd
Phase 2 Unknown
NCT06003998 2023-08-22
INTERACT-II
Catharina Ziekenhuis Eindhoven
Phase 2 Unknown
NCT04659382 2023-08-18
SIRTCI
Federation Francophone de Cancerologie Digestive
Phase 2 Unknown
NCT03950154 2023-08-01
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT04724239 2023-08-01
Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT05799820 2023-05-25
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
Qilu Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT05659290 2023-01-06
Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT05314101 2022-08-23
TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT04683965 2022-08-02
Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT04733963 2022-07-26
Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT05438108 2022-06-29
SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC
Huazhong University of Science and Technology
Phase 2 Unknown
NCT05103020 2021-11-02
Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases
Yonsei University
Phase 2 Unknown
NCT04188145 2021-10-28
BEVAMAINT
Centre Hospitalier Universitaire Dijon
Phase 3 Unknown
NCT04988191 2021-08-03
Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer
Peking University
Phase 1/2 Unknown
NCT04788381 2021-03-09
The Effects of Preoperative Bevacizumab on Perioperative Complications
Second Affiliated Hospital, School of Medicine, Zhejiang University
Unknown
NCT04527068 2020-09-17
BEVTOR
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT02226289 2020-09-02
BATTLE
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Unknown
NCT04525326 2020-08-25
Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases
Fudan University
Phase 3 Unknown
NCT04213222 2020-08-11
ROBOT
Peking University People's Hospital
Unknown
NCT04397601 2020-05-21
ARBITRATION
National Cancer Institute, Naples
Unknown
NCT04380103 2020-05-08
A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer
ChineseAMS
Phase 1/2 Unknown
NCT02339116 2020-02-05
TRIBE2
Gruppo Oncologico del Nord-Ovest
Phase 3 Unknown
NCT01802645 2019-09-11
CELIM2
Technische Universität Dresden
Phase 2 Unknown
NCT03711240 2019-03-13
CBL
National Cheng-Kung University Hospital
Phase 2 Unknown
NCT03271255 2019-01-23
Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)
Shenzhen People's Hospital
Phase 2 Unknown
NCT03511183 2018-05-01
XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer
Harbin Medical University
Phase 2 Unknown
NCT03303495 2017-10-06
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
Sun Yat-sen University
Phase 3 Unknown
NCT02350530 2016-09-20
FORBES
Sun Yat-sen University
Phase 2 Unknown
NCT02842294 2016-07-22
COBEQOL
Centre Hospitalier Universitaire de Besancon
Unknown
NCT02591667 2016-04-05
CARCINOSIS
Medical University of Vienna
Phase 2 Unknown
NCT02515734 2015-08-05
DEEPER
Japan Clinical Cancer Research Organization
Phase 2 Unknown
NCT01860144 2015-05-19
An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer
Peking University
Unknown
NCT01912443 2014-04-28
Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer
Sun Yat-sen University
Unknown
NCT00433927 2014-03-14
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
Ludwig-Maximilians - University of Munich
Phase 3 Unknown
NCT00442637 2013-12-12
CAIRO3
Dutch Colorectal Cancer Group
Phase 3 Unknown
NCT00974389 2013-08-12
S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01763450 2013-01-29
Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT01679327 2012-09-06
Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
ChineseAMS
Phase 2 Unknown
NCT01311050 2011-12-13
A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer
King Faisal Specialist Hospital & Research Center
Unknown
NCT00659022 2011-09-12
Neo-adjuvant Therapy and the Effect on Synchronous Metastatic Growth
Radboud University Medical Center
Phase 2 Unknown
NCT00438737 2011-09-02
Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00544011 2011-06-27
Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01249521 2010-11-30
Vengeance
Austin Health
Phase 2 Unknown
NCT00513266 2009-08-07
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
National Cancer Institute (NCI)
Phase 2 Unknown